natgillin/translations-raw huggingface dataset:
In addition, Zinbryta reduced clinically meaningful worsening in the patient- reported physical impact of MS (≥7.5 point worsening from baseline to week 96 in the MSIS-29 physical score) compared to interferon beta-1a (intramuscular).
Poleg tega je zdravilo Zinbryta zmanjšalo klinično pomembno poslabšanje fizičnega vpliva multiple skleroze, o katerem poročajo bolniki, (poslabšanja za ≥ 7,5 točk od izhodišča do 96. tedna v fizičnem seštevku MSIS-29) v primerjavi z interferonom beta-1a (intramuskularano).
In addition,dry mouth that could have a damaging effect on teeth and membranes of the mouth has been reported during long-term treatment with this medicine in combination therapy with and alpha interferon.
Poleg tega so med dolgotrajnim zdravljenjem s kombinacijo s tem zdravilom in interferona alfa-2b poročali o suhih ustih, ki imajo lahko škodljiv vpliv na zobe in ustno sluznico.
In additional extension trials, patients receiving elosulfase alfa 2 mg/kg every week, showed maintenance of initial improvement in endurance and sustained reduction of urinary KS up to 156 weeks.
V dodatnih podaljšanjih preskušanja so pri bolnikih, ki so vsak teden prejemali elosulfazo alfa v odmerku 2 mg/kg telesne mase, opazili ohranjanje začetnega izboljšanja vzdržljivosti in trajanje znižanja ravni KS v urinu do 156 tednov.
In adolescents (12 years or older), there are no recommended dose modifications.
Pri mladostnikih (starih 12 let ali več) ni priporočenih prilagoditev odmerka.
In adolescents (12-17 years) relative change in % predicted FEV1 compared to control improved by 3.31% (95% CI -2.29, 8.90, N=55) and 0.42% (95% CI -5.45, 6.29, N=94) over 26 weeks (p=0.245 and 0.888) respectively.
Pri mladostnikih (12–17 let) se je v 26 tednih odstotkovna vrednost napovedanega FEV1 v primerjavi s kontrolno skupino v prvi študiji relativno izboljšala za 3,31 % (95-odstotni IZ: -2,29; 8,90, n=55, p=0,245), v drugi študiji pa za 0,42 % (95-odstotni IZ: -5,45; 6,29, n=94, p=0,888).
In adolescents (age 12–16 years, n=14), the steady-state distribution volume was 7.85.1 l, half-life was 9.13.9 days and clearance was 3119 ml/h.
Pri mladostnikih (starost 12–16 let, n = 14) je bil porazdelitveni volumen v stanju ravnovesja 7,8  5,1 l, razpolovni čas je bil 9,1  3,9 dni, očistek pa 31  19 ml/h.
In adolescents (aged from 12 to 17 years and weighing at least 40 kg) infected with HIV-1 without resistance to the integrase class, the recommended dose of dolutegravir is 50 mg once daily.
Pri mladostnikih (starih od 12 do 17 let, ki tehtajo vsaj 40 kg), okuženih z virusom HIV-1, brez odpornosti na zdravila iz skupine zaviralcev integraze, je priporočeni odmerek dolutegravirja 50 mg enkrat na dan.
In adolescents (ages 12 to 17 years) receiving caspofungin at 50 mg/m2 daily (maximum 70 mg daily), the caspofungin plasma AUC0-24 hr was generally comparable to that seen in adults receiving caspofungin at 50 mg daily.
Pri mladostnikih (starih od 12 do 17 let), ki so dobivali kaspofungin v odmerku 50 mg/m2 na dan (največ 70 mg na dan) je bila AUC0-24h kaspofungina v plazmi na splošno primerljiva kot pri odraslih, ki so dobivali 50 mg kaspofungina na dan.
In adolescents of 12 years and older, Ketek is used to treat infections of the throat.
Pri mladostnikih starih 12 let ali več se z zdravilom Ketek zdravi okužbe žrela.
In adolescents weighing < 51 kg, a 23% higher exposure was observed than in adolescents weighing ≥ 51 kg.
Pri mladostnikih s telesno maso < 51 kg so opažali za 23% večjo izpostavljenost kot pri mladostnikih s telesno maso ≥ 51 kg.
in adolescents who have not reached adult size. if you live permanently at heights above 2439 meters (8000 feet).
pri mladostnikih, ki še niso dosegli odrasle velikosti. če stalno živite na višini nad 2439 metrov.
In adolescents with chronic hepatitis B, 88% of patients taking Viread had a viral level below 400 copies/ml after 72 weeks compared with 0% of those taking placebo.
Pri mladostnikih s kroničnim hepatitisom B je imelo 88 % bolnikov, ki so jemali zdravilo Viread, po 72 tednih raven virusa pod 400 kopij/ml v primerjavi z 0 % bolnikov, ki so jemali placebo.
In adolescents, there was no benefit of adding Viread to existing treatment compared with adding placebo.
Pri mladostnikih ni bilo opaziti koristi dodajanja zdravila Viread obstoječemu zdravljenju v primerjavi z dodajanjem placeba.
in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older, in adult and paediatric patients with other anaemias aged 2 years and older.
pri odraslih in pediatričnih bolnikih, ki imajo beta talasemijo major in preobremenitev z železom zaradi manj pogostih transfuzij krvi (<7 ml/kg/mesec koncentriranih eritrocitov) in so stari 2 leti ali več, pri odraslih in pediatričnih bolnikih z drugimi anemijami, ki so stari 2 leti ali več.
In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML., on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP.
Pri odraslih in pediatričnih bolnikih temelji učinkovitost imatiniba na celotni hematološki in citogenetični odzivnosti in preživetju brez napredovanja bolezni pri KML, na hematološki in citogenetični odzivnosti pri Ph+ ALL in MDS/MPD, na hematološki odzivnosti pri HES/CEL ter na objektivni odzivnosti odraslih bolnikov z neresektabilnimi in/ali metastatskimi DFSP.
In adult and paediatric studies, patients received either phenytoin or benzodiazepines as seizure prophylaxis treatment. (see sections 4.4 and 4.5).
V študijah pri odrasli in pediatrični populaciji so bolniki kot profilakso proti epileptičnim napadom preventivno prejemali fenitoin ali benzodiazepine (glejte poglavji 4.4 in 4.5).
In adult and paediatric studies, patients received either phenytoin or benzodiazepines as seizure prophylaxis treatment. (see sections 4.4 and 4.5).
V študijah pri odraslih in pediatrični populaciji so kot profilakso proti epileptičnim napadom bolniki preventivno prejemali fenitoin ali benzodiazepine (glejte poglavji 4.4 in 4.5).
In adult bitches, the first treatment should be administered preferably in metoestrus.
Pri odraslih psicah ga je najbolje prvič uporabiti v metestrusu.
In adult Crohn’s disease studies, higher incidences of malignant and serious infection-related adverse events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with Humira alone.
V študijah Chronove bolezni pri odraslih so pri sočasni uporabi zdravila Humira in azatioprina/6- merkaptopurina opazili večjo incidenco malignih in resnih z okužbo povezanih neželenih dogodkov kot pri zdravljenju samo z zdravilom Humira.
In adult dogs, after repeated oral administration of spinosad and milbemycin oxime for six consecutive months, increases in elimination half-lives were observed up to month 3.
Pri odraslih psih večkratnoperoralno dajanje spinosada in milbemicin oksima za šest zaporednih mesecev povzroči povečanje končnega razpolovnega časa do 3. meseca.
In adult females:
Pri odraslih ženskah:
In adult liver, kidney, and heart transplant patients, values of 4.1 L/h, 6.7 L/h, and 3.9 L/h, respectively, have been observed.
Pri odraslih bolnikih so po presaditvi jeter opazili vrednost 4,1 L/h, po presaditvi ledvice 6,7 L/h in po presaditvi srca 3,9 L/h.
In adult males:
Pri odraslih moških:
in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.
pri odraslih moških s povečanim tveganjem za zlome vključno s tistimi z nedavnim zlomom kolka po lažji poškodbi.
in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.
pri odraslih moških s povečanim tveganjem za zlome, vključno s tistimi z nedavnim zlomom kolka po lažji poškodbi.
in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.
pri odraslih moških, s povečanim tveganjem za zlome, vključno s tistimi z nedavnim zlomom kolka po lažji poškodbi.
in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.
s povečanim tveganjem za zlome vključno s tistimi z nedavnim zlomom kolka po lažji poškodbi.
in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture..
pri odraslih moških s povečanim tveganjem za zlome, vključno s tistimi z nedavnim zlomom kolka po lažji poškodbi.
in adult men at increased risk of fracture.
pri odraslih moških pri katerih obstaja povečano tveganje za zlom.
in adult men at increased risk of fracture.
pri odraslih moških, pri katerih obstaja povečano tveganje za zlom.
in adult men, at high risk of fracture, for whom other alternative treatments are not possible.
pri odraslih moških, z visokim tveganjem za zlome, pri katerih druga alternativna zdravljenja niso mogoča.
in adult men, at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.
pri odraslih moških, z velikim tveganjem za zlome, pri katerih zdravljenje z drugimi zdravili, ki so odobrena za zdravljenje osteoporoze, zaradi kontraindikacij ali neprenašanja ni mogoče.
In adult men, Bemfola is used: together with another medicine called “human Chorionic Gonadotropin” (hCG) to help produce sperm in men that are infertile due to a low level of certain hormones.
Pri odraslih moških se zdravilo Bemfola uporablja: skupaj z zdravilom, ki se imenuje „humani horionski gonadotropin“ (hCG) in pomaga pri tvorbi sperme pri tistih moških, ki so neplodni zaradi nizke ravni nekaterih hormonov.
In adult men, Ovaleap is used: in combination with a medicine called “human chorionic gonadotropin” (hCG) to help produce sperm in men that are infertile due to low levels of certain hormones.
Pri odraslih moških se zdravilo Ovaleap uporablja: v kombinaciji z zdravilom "humani horionski gonadotropin" (hCG) za pomoč pri tvorbi sperme pri moških, ki so neplodni zaradi nizke ravni nekaterih hormonov.
in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance
pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) nezadostno nadzorovanih z dieto in gibanjem, pri katerih je metformin, zaradi kontraindikacij ali neprenašanja, neprimeren.
in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
Kot monoterapija pri odraslih bolnikih (zlasti bolnikih s čezmerno telesno maso), ki imajo bolezen nezadostno urejeno z dieto in telesno dejavnostjo in za katere metformin ni primeren zaradi kontraindikacij ali neprenašanja.
in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;
pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso), nezadostno nadzorovanih z dieto in gibanjem, pri katerih je metformin, zaradi kontraindikacij ali neprenašanja, neprimeren.
In adult patients converted to Advagraf, an initial oral dose of 0.15 mg/kg/day should be administered once daily in the morning.
Pri odraslih bolnikih je pri prehodu na zdravljenje z zdravilom Advagraf treba uvesti začetni peroralni odmerek 0,15 mg/kg/dan, ki se daje enkrat na dan, in sicer zjutraj.
In adult patients Imatinib Accord is used to treat a late stage of chronic myeloid leukaemia called “blast crisis.”
Zdravilo Imatinib Accord se pri odraslih bolnikih uporablja za zdravljenje kronične mieloične levkemije v poznem stadiju, imenovanem “blastna kriza”.
in adult patients on peritoneal dialysis to treat symptomatic anaemia associated with chronic renal failure (kidney disease).
pri odraslih na peritonealni dializi, kot zdravilo za simptomatsko anemijo v zvezi s kronično ledvično okvaro (bolezen ledvic).
in adult patients receiving chemotherapy for solid tumours, malignant lymphoma (cancer of the lymphatic system) or multiple myeloma (bone marrow cancer) to treat anaemia and reduce the need for a blood transfusion, if the doctor decides there may be a high risk of needing a blood transfusion.
za zdravljenje anemije in zmanjšanje potrebe po krvnih transfuzijah pri odraslih bolnikih, ki prejemajo kemoterapijo zaradi čvrstih tumorjev, malignih limfomov (rak limfnega sistema) ali multiplega mieloma (rak kostnega mozga) in za katere je bil zdravnik mnenja, da je zelo verjetno, da bi potrebovali transfuzijo krvi.
In adult patients who are eligible for a ‘reduced-intensity’ conditioning regimen, Busilvex is given right after treatment with another medicine, fludarabine.
Pri odraslih bolnikih, ki so upravičeni do pripravljalnega režima zdravljenja z zmanjšano jakostjo, se zdravilo Busilvex daje neposredno po zdravljenju z drugim zdravilom, fludarabinom.
In adult patients who are eligible for a ‘reduced-intensity’ conditioning regimen, Busulfan Fresenius Kabi is given right after treatment with another medicine, fludarabine.
Pri odraslih bolnikih, ki so primerni za pripravljalni režim zdravljenja z zmanjšano jakostjo zdravila, se zdravilo Busulfan Fresenius Kabi daje neposredno po zdravljenju z drugim zdravilom, fludarabinom.
in adult patients whose blood pressure is not controlled enough with amlodipine alone. in adult patients who already receive telmisartan and amlodipine from separate tablets and who wish to take instead the same doses in one tablet for convenience.
pri odraslih bolnikih, katerim sam amlodipin ne zadošča za uravnavanje krvnega tlaka, pri odraslih bolnikih, ki že jemljejo telmisartan in amlodipin ločeno in želijo jemati enaka odmerka v eni tableti.
in adult patients whose blood pressure is not controlled enough with amlodipine. in adult patients who already receive telmisartan and amlodipine from separate tablets and who wish to take instead the same doses in one tablet for convenience.
pri odraslih bolnikih, katerim amlodipin ne zadošča za uravnavanje krvnega tlaka, pri odraslih bolnikih, ki že jemljejo telmisartan in amlodipin ločeno in želijo jemati enaka odmerka v eni tableti.
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
Pri odraslih bolnikih z atrijsko fibrilacijo, ki imajo vsaj en dejavnik tveganja za žilne dogodke in ki niso primerni za zdravljenje z antagonisti vitamina K (VKA) ter imajo majhno tveganje za krvavitev, je klopidogrel v kombinaciji z ASA indiciran za preprečevanje aterotrombotičnih in trombemboličnih dogodkov, vključno z možgansko kapjo.
In adult patients with clinically uncertain Parkinsonian Syndromes, for example those with early symptoms, in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy.
Pri odraslih bolnikih, pri katerih obstaja sum parkinsonskih sindromov kot na primer tistih z zgodnjimi simptomi, kar omogoči ločevanje esencialnega tremorja od parkinsonskih sindromov, povezanih z idiopatsko Parkinsonovo boleznijo, multiplo sistemsko atrofijo in progresivno supranuklearno paralizo.
In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%) treated with adalimumab monotherapy.
Pri odraslih bolnikih s psoriazo so protitelesa proti adalimumabu ugotovili pri 77 od 920 preiskovancev (8,4 %), ki so dobivali monoterapijo z adalimumabom.
In adult patients with psoriasis, the mean steady-state trough concentration was 5 μg/mL during adalimumab 40 mg every other week monotherapy treatment.
Pri odraslih bolnikih s psoriazo je bila povprečna koncentracija v stanju dinamičnega ravnovesja med monoterapijo z adalimumabom 40 mg vsak drugi teden 5 μg/ml.
In adult patients with psoriasis, the mean steady-state trough concentration was 5 g/mL during adalimumab 40 mg every other week monotherapy treatment.
Pri odraslih bolnikih s psoriazo je bila povprečna najmanjša koncentracija v stanju dinamičnega ravnovesja med monoterapijo s 40 mg adalimumaba vsak drugi teden 5 µg/ml.
In adult patients with psoriasis, the mean steady-state trough concentration was 5 g/ml during adalimumab 40 mg every other week monotherapy treatment.
Pri odraslih bolnikih s psoriazo je bila povprečna najmanjša koncentracija v stanju dinamičnega ravnovesja med monoterapijo s 40 mg adalimumaba vsak drugi teden 5 g/ml.
In adult patients with renal dysfunction requiring dialysis an additional 200 mg dose of nevirapine immediate-release following each dialysis treatment is recommended.
Pri odraslih bolnikih z ledvično disfunkcijo, ki se zdravijo z dializo, priporočamo dodaten odmerek nevirapina s takojšnim sproščanjem 200 mg po vsaki dializi.
In adult patients, in cases where once daily dosing is considered necessary for the management of the patient, lopinavir/ritonavir tablets may be administered as 800/200 mg (four 200/50 mg tablets) once daily with or without food.
Če je za obravnavo bolnika treba pretehtati uporabo enkrat na dan, pride pri odraslih bolnikih v poštev uporaba tablet lopinavirja/ritonavirja v odmerku 800 mg/200 mg (štiri 200 mg/50 mg tablete) enkrat na dan s hrano ali brez nje.
In adult patients, in cases where once-daily dosing is considered necessary for the management of the patient, Kaletra tablets may be administered as 800/200 mg (four 200/50 mg tablets) once daily with or without food.
Če je za obravnavo bolnika treba pretehtati uporabo enkrat na dan, pride pri odraslih bolnikih v poštev uporaba tablet zdravila Kaletra v odmerku 800/200 mg (štiri tablete 200/50 mg) enkrat na dan s hrano ali brez nje.
In adult patients, in cases where once-daily dosing is considered necessary for the management of the patient, Kaletra tablets may be administered as 800/200 mg (four 200/50 mg tablets) once daily with or without food.
Če je za obravnavo bolnika treba pretehtati uporabo enkrat na dan, pride pri odraslih bolnikihv poštev uporaba tablet zdravila Kaletra v odmerku 800/200 mg (štiri tablete 200/50 mg) enkrat na dan s hrano ali brez nje.
In adult patients, this dose is given directly into your blood stream (into a vein), either as an infusion lasting about 30 minutes or as an injection lasting about 2 minutes.
Odrasli bolniki prejmete ta odmerek direktno v krvni obtok (v veno) bodisi kot infuzijo, ki traja okrog 30 minut, ali kot injekcijo, ki traja približno 2 minuti.
In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease.
Pri odraslih bolnikih v je pomoč pri razlikovanju verjetne demence z Lewyjevimi telesci od Alzheimerjeve bolezni.
In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%) was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).
Pri odraslih bolnikih s psoriazo v plakih, ki so prejemali dolgotrajno monoterapijo z adalimumabom in so sodelovali v študiji prenehanja uporabe in ponovnega zdravljenja, je bil delež protiteles proti adalimumabu po ponovnem zdravljenju (11 od 482 bolnikov, 2,3 %) podoben kot pred prenehanjem uporabe (11 od 590 bolnikov, 1,9 %).
In adults (aged 18 and over), Enbrel can be used for moderate or severe rheumatoid arthritis, psoriatic arthritis, severe axial spondyloarthritis including ankylosing spondylitis, and moderate or severe psoriasis – in each case usually when other widely used treatments have not worked well enough or are not suitable for you.
Pri odraslih (starih 18 let in več) se zdravilo Enbrel lahko uporablja pri zdravljenju zmernega ali hudega revmatoidnega artritisa, psoriatičnega artritisa, hudega aksialnega spondilartritisa, vključno z ankilozirajočim spondilitisom, in zmerne ali hude luskavice – v vseh primerih običajno šele po neuspešnem zdravljenju z drugimi običajnimi oblikami zdravljenja, ali če te oblike zdravljenja za vas niso primerne.
In adults (aged 18 years or over) it can be given at any time, provided that it is at the same time each day.
Odrasli bolniki (starejši od 18 let) lahko injekcijo prejmejo kadar koli čez dan, vendar vsak dan ob istem času.
In adults (aged 18 years or over), the recommended dose of Avonex is 30 micrograms, given by injection into a muscle once a week.
Pri odraslih (starejših od 18 let) je priporočeni odmerek zdravila Avonex 30 mikrogramov, ki se daje z injekcijo v mišico enkrat na teden.
In adults 18 to 60 years of age, the most frequently reported adverse reactions after vaccination were injection site pain (76.6%), muscle aches (46.8%), fatigue (43.6%), headache (25.3%) and joint pain (13.5%).
Pri odraslih v starosti od 18 do 60 let so bili najpogosteje zabeleženi neželeni učinki po cepljenju: bolečina na mestu injiciranja (76,6 %), boleče mišice (46,8 %), utrujenost (43,6 %), glavobol (25,3 %) in bolečine v sklepih (13,5 %).
In adults 18 to 64 years of age, the most frequently reported adverse reactions after vaccination were injection site pain (80.5%), muscle aches (37.2%), fatigue (25.2%), headache (25.1%), joint pain (17.7%) and shivering (11.1%).
Pri odraslih, starih od 18 do 64 let, so bili najpogosteje zabeleženi neželeni učinki cepljenja bolečina na mestu injiciranja (80,5 %), bolečine v mišicah (37,2 %), utrujenost (25,2 %), glavobol (25,1 %), bolečine v sklepih (17,7 %) in drgetanje (11,1 %).
In adults and adolescents (aged 12 years and over), the recommended dose of Kaletra is three capsules or two 200/50-mg tablets twice a day.
Priporočeni odmerek zdravila Kaletra za odrasle in mladostnike (starejše od 12 let) je tri kapsule ali dve 200/50-miligramski tableti dvakrat na dan.
In adults and adolescents 12 to 17 years old, Cinryze can raise the amount of C1 inhibitor in the blood and either prevent ( routinely or prior to undergoing medical or dental procedures) these swelling attacks from occurring or stop swelling attacks once they have begun.
Pri odraslih in mladostnikih, starih 12 do 17 let, zdravilo Cinryze lahko zviša koncentracijo zaviralca C1 v krvi in bodisi prepreči (rutinsko ali pred medicinskimi ali zobozdravstvenimi posegi), da bi se ti napadi otekanja pojavljali, bodisi tak napad zaustavi, če se je že začel.
In adults and adolescents aged 11 and over, two injections are given (at an interval of at least one month).
Odraslim in mladostnikom, starejšim od 11 let, se injicirata dva odmerka (v razmiku vsaj enega meseca).
in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis (see section 4.4).
pri odraslih in otrocih, starih 1 do 18 let, ki se zdravijo s hemodializo, in odraslih bolnikih, ki se zdravijo s peritonealno dializo (glejte poglavje 4.4).
In adults Clopidogrel Teva Pharma B.V. reduces the risk of blood clots forming which in turn reduces the risk of serious conditions such as heart attack and stroke from occurring.
Zdravilo Klopidogrel Teva Pharma B.V. jemljejo odrasali za preprečavanje nastanka krvnih strdkov (trombov) ter tako preprečuje pojav resnih dogodkov, kot je srčni napad in kap.
In adults it also prevents this condition from returning in patients who have responded to the treatment with ABILIFY oral solution.
Zdravilo tudi preprečuje ponovitve bolezni pri odraslih bolnikih, ki so se odzvali na zdravljenje s peroralno raztopino ABILIFY.
In adults it also prevents this condition from returning in patients who have responded to the treatment with ABILIFY orodispersible tablets.
Zdravilo tudi preprečuje ponovitve bolezni pri odraslih bolnikih, ki so se odzvali na zdravljenje z zdravilom ABILIFY orodisperzibilne tablete.